Patents Represented by Attorney Thomas S. Borecki
-
Patent number: 5984891Abstract: A portable pump apparatus for use in CAPD is provided as well as a method for providing CAPD to a patient. The portable pump apparatus for CAPD has a housing containing a pump, and a power supply, preferably a rechargeable battery, connected to the housing and electrically connected to drive the pump. A control knob on the housing is constructed and arranged to adjust the speed of the pump. A cover is mounted to the housing to enclose the pump. The cover has an inlet port and an outlet port to securely hold a tube thereunder. The portable pump apparatus for CAPD further has a display for providing drainage information and a clip so that the apparatus can be worn by a patient.Type: GrantFiled: January 7, 1998Date of Patent: November 16, 1999Assignee: Baxter International Inc.Inventors: Michael R. Keilman, Kelly B. Smith
-
Patent number: 5968966Abstract: Methods and compositions for treating renal failure patients are provided. Pursuant to the present invention, a renal failure patient is provided with an intravenous or dialysis solution that includes a therapeutically effective amount of L-carnosine. In part, the L-carnosine will prevent the renal failure patient from developing L-carnosine deficiency.Type: GrantFiled: October 9, 1997Date of Patent: October 19, 1999Assignee: Baxter International Inc.Inventor: Jonas Bergstrom
-
Patent number: 5965533Abstract: The present invention provides a peritoneal dialysis solution that contains atrial natriuretic peptide (ANP), a derivative of ANP, an analogue of ANP, a substance that binds ANP to clearance receptors or a substance that promotes ANP synthesis, which results in an increased net ultrafiltration and increased sodium clearance experienced in peritoneal dialysis patients.Type: GrantFiled: May 23, 1997Date of Patent: October 12, 1999Assignees: Baxter International Inc., Miles G. JohnstonInventors: Chi J. Chen, Ty R. Shockley, Miles G. Johnston
-
Patent number: 5955450Abstract: Peritoneal dialysis solutions are specially formulated for use during and immediately after an episode of peritonitis. The solutions include one or more additives to minimize the injury and physiological effects that peritonitis can cause. One additive is a mixture of amino acids sufficient to maintain a positive nitrogen balance, at least one of the amino acids being present in a dipeptide form. Another additive is a compound that scavenges free radicals generated by peritoneal macrophages activated by the peritonitis. Another additive is chondroitin sulfate that changes the permeability of the peritoneal membrane during subsequent dialysis using solutions free of chondroitin sulfate. Another additive is the degradation products of hyaluronic acid to enhance the regeneration of the peritoneal mesothelium without fibrosis.Type: GrantFiled: August 16, 1996Date of Patent: September 21, 1999Assignee: Baxter International Inc.Inventors: Andrzej Breborowicz, Dimitrios G. Oreopoulos
-
Patent number: 5948385Abstract: An antimicrobial material incorporated with a molecular halogen is provided. The antimicrobial material includes a plastic material and a molecular halogen entrapped within the plastic material. A directional release material is also provided in the present application. The directional release material allows for the control of the rate and site of halogen release. Still further, method of impregnating a plastic material are also provided.Type: GrantFiled: September 30, 1997Date of Patent: September 7, 1999Assignee: Baxter International Inc.Inventors: John R. Chapman, Ying-Cheng Lo, Winnie Kubey, Clifford J. Holmes, David Bell
-
Patent number: 5938634Abstract: A variable pressure drive peritoneal dialysis system has a pneumatic pressure system for purging and controlling a flow of dialysate through a disposable dialysate cassette of a disposable dialysate delivery set. The pneumatic pressure system has a variable-opening flow proportional valve for supplying air at selected profiled pressure or vacuum to a pneumatic interface. The disposable dialysate cassette has a diaphragm pump actuable by the profiled air pressure or vacuum to move dialysate to and from a patient via the disposable dialysate delivery set at a desired profiled dialysate pressure.Type: GrantFiled: August 23, 1996Date of Patent: August 17, 1999Assignee: Baxter International Inc.Inventor: Warren J. Packard
-
Patent number: 5925011Abstract: A system and a method are provided for admixing solutions. The system includes containers separately accessible by one or more pumps for mixture of the solutions in a container immediately before administration to a peritoneal cavity of a patient. Alternatively, the system and method allow for direct administration of the mixed solution to the peritoneal cavity of a patient without intermediate mixing thereof. The solutions may be mixed in predetermined ratios as input to the system prior to delivery.Type: GrantFiled: October 10, 1995Date of Patent: July 20, 1999Assignee: Baxter International Inc.Inventors: Dirk Faict, Chi J. Chen, Francesco Peluso, Robert Warren Childers, Patrick Balteau, Vital Eerlingen, Paul Frederick Emerson, Lisa Colleran
-
Patent number: 5881879Abstract: A container system for containing and preserving gas generating solutions such as bicarbonate-containing solutions is provided. The system includes an outer container or barrier that is gas impermeable. The system also includes an indicator for visually indicating when gas has been permitted to leak or escape from the outer container thereby changing the physical characteristics of the gas generating solution.Type: GrantFiled: February 7, 1997Date of Patent: March 16, 1999Assignee: Baxter International Inc.Inventors: Dirk Faict, Anne Leyssens, Annick Duponchelle, Jean-Pierre Hartman
-
Patent number: 5876396Abstract: A system and a method for administering a solution (12) from a container (10) to a patient (35) are provided. The container (10) is divided into a solution side (16) and a drain side (18) separated by a tear line (20). The solution side (16) and the drain side (18) are in fluid communication with one another and with a port (28) that connects to the patient (35). The container (10) is separable at the tear line (20) such that contents of a peritoneum cavity of the patient (35) may be drained into the drain side (18) of the container (10). Then, the solution (12) from the solution side (16) of the container (10) may be drained from the container (10) into the patient (35).Type: GrantFiled: September 27, 1996Date of Patent: March 2, 1999Assignee: Baxter International Inc.Inventors: Ying-Cheng Lo, Marc Bellotti
-
Patent number: 5873853Abstract: A portable pump apparatus for use in CAPD is provided as well as a method for providing CAPD to a patient. The portable pump apparatus for CAPD has a housing containing a pump, and a power supply, preferably a rechargeable battery, connected to the housing and electrically connected to drive the pump. A control knob on the housing is constructed and arranged to adjust the speed of the pump. A cover is mounted to the housing to enclose the pump. The cover has an inlet port and an outlet port to securely hold a tube thereunder. The portable pump apparatus for CAPD further has a display for providing drainage information and a clip so that the apparatus can be worn by a patient.Type: GrantFiled: May 23, 1995Date of Patent: February 23, 1999Assignee: Baxter International Inc.Inventors: Michael R. Keilman, Kelly B. Smith
-
Patent number: 5871649Abstract: The present invention provides an improved affinity membrane device and method for the effective removal of target molecules in plasma. The affinity membrane device is designed for use in an extracorporeal blood circuit and can be employed concurrently with other therapeutic processes for the purification of blood. The device of the present invention consists of hollow fiber membranes having specified dimensions and transfer properties, ligand immobilized to the pore surface of the hollow fibers, and a housing to encase the hollow fibers and allow appropriate entry and exit of the blood. In a preferred embodiment, specific immobilization chemistries are utilized to attach the ligands to the hollow fibers for optimal function.Type: GrantFiled: July 11, 1997Date of Patent: February 16, 1999Assignee: Baxter International Inc.Inventors: Norma J. Ofsthun, Paul J. Soltys, Gretchen A. Kunas
-
Patent number: 5868936Abstract: The present invention provides an improved affinity membrane device and method for the effective removal of target molecules in plasma. The affinity membrane device is designed for use in an extracorporeal blood circuit and can be employed concurrently with other therapeutic processes for the purification of blood. The device of the present invention consists of hollow fiber membranes having specified dimensions and transfer properties, ligand immobilized to the pore surface of the hollow fibers, and a housing to encase the hollow fibers and allow appropriate entry and exit of the blood. In a preferred embodiment, specific immobilization chemistries are utilized to attach the ligands to the hollow fibers for optimal function.Type: GrantFiled: June 20, 1996Date of Patent: February 9, 1999Assignee: Baxter International Inc.Inventors: Norma J. Ofsthun, Paul J. Soltys, Gretchen A. Kunas
-
Patent number: 5865308Abstract: A device, a system and a method are provided for controllably releasing a product (26) into a container (10) in which the product (26) is mixed with another product contained within an interior (14) of the container 10. The device (12) releases the product (26) due to variations in temperature or pressure that the system experiences during an autoclaving or sterilization procedure, for example. Materials and shapes of the members (20, 20a, 20b, 22) of the device (12) are selected such that the members (20, 20a, 20b, 22) react or otherwise move within the device in a predetermined manner in response to changes in temperature or pressure. As a result, products (26) within the device (12) may be maintained separately from products within the interior (14) of the container (10) in which the device (12) is held. Prior to administration of a solution within the container (10), the product (26) within the device (12) may be mixed with the solution or other product in the container (10) in a controllable fashion.Type: GrantFiled: October 29, 1996Date of Patent: February 2, 1999Assignee: Baxter International Inc.Inventors: Chuan Qin, Yuanpang Samuel Ding, Chi Chen, Jerry Ripley
-
Patent number: 5865793Abstract: A system and a method for administering a solution (12) from a container (10) to a patient (35) are provided. The container (10) is divided into a solution side (16) and a drain side (18) separated by a tear line (20). The solution side (16) and the drain side (18) are in fluid communication with one another and with a port (28) that connects to the patient (35). The container (10) is separable at the tear line (20) such that contents of a peritoneum cavity of the patient (35) may be drained into the drain side (18) of the container (10). Then, the solution (12) from the solution side (16) of the container (10) may be drained from the container (10) into the patient (35).Type: GrantFiled: September 2, 1997Date of Patent: February 2, 1999Assignee: Baxter International Inc.Inventors: Ying-Cheng Lo, Marc Bellotti
-
Patent number: 5849179Abstract: An improved on-line, real time hemodialysis monitoring system for hemodialysis treatment, quantitates the rate and amount of a constituent, such as urea, removed during the hemodialysis treating by measuring the constituent concentrations as a function of time in the spent dialysate effluent from a hemodialysis machine. A quantity of the spent dialysate effluent is removed from the dialysate effluent waste line periodically for testing. A urea concentration time profile can be analyzed to determine the urea removal, KT/V, URR, SRI, and normalized protein catabolic rate (nPCR) indices. The hemodialysis monitoring system preferably can obtain a dialysate sample equilibrated with the blood prior to the start of a hemodialysis treatment.Type: GrantFiled: May 20, 1996Date of Patent: December 15, 1998Assignee: Baxter International Inc.Inventors: Paul Emerson, Prakash Keshaviah, David A. Luhring
-
Patent number: 5840252Abstract: The present invention provides improved methods for manufacturing solutions including medical solutions. To this end, in an embodiment, a method for preparing a medical solution is provided comprising the steps of: placing a solution in a gas permeable container; and allowing carbon dioxide to permeate through the container until a desired pH is achieved.Type: GrantFiled: October 18, 1996Date of Patent: November 24, 1998Assignee: Baxter International Inc.Inventor: Joseph A. Giertych
-
Patent number: 5840151Abstract: An apparatus for forming coiled tubular assemblies is provided. The apparatus includes a pair of dies formed from a radio frequency (RF) conducting material. The dies each have contoured leading surfaces with these surfaces having grooves with lands between adjacent grooves. The lands of the dies cooperate to form web forming chambers when the pair of dies are moved together in their operative position. In the operative position, the tubes are captured in the aligned grooves with portions of the tubes being squeezed or extruded into the web forming chamber. Application of RF energy to the dies causes the tube portions in the chambers to plasticize and form webs between the coils of the tubes with a predetermined configuration substantially the same as that of the web forming chambers. Both radially coiled and axially coiled tube assemblies are contemplated by the invention. In addition, an easy-to-separate or peel tubular assembly is formed with the above apparatus.Type: GrantFiled: November 13, 1996Date of Patent: November 24, 1998Assignee: Baxter International Inc.Inventor: John M. Munsch
-
Patent number: 5834178Abstract: A flush-storage solution for flushing blood out of a donor organ and cold-storing the donor organ prior to transplantation is provided. The solution of the present invention includes mannitol as an impermeable solute. The present invention also provides an improved method of flushing and cold-storing donor organs as well as an improved method of transplanting donor organs into a recipient.Type: GrantFiled: July 9, 1997Date of Patent: November 10, 1998Assignee: Wayne State UniversityInventors: Paul C. Churchill, Monique C. Churchill
-
Patent number: 5827820Abstract: The subject matter of this invention concerns an aqueous peritoneal dialysis solution which is obtained immediately prior to administration from two individual solutions, the first of which contains an osmotically active substance and the second of which contains bicarbonate ions, with the first individual solution containing anions of mono- and/or dicarboxylic acids and having a pH value of 4.5-5.8 and with the second individual solution containing an amino acid component or a peptide component and having a pH value of 7.2 to 10.0, and with the ready-to-use solution containing 23 to 26 mmoles/L bicarbonate ions and having a CO.sub.2 partial pressure of 25-70 mmHg and a pH value of 7.2 to 7.Type: GrantFiled: June 27, 1997Date of Patent: October 27, 1998Assignee: Baxter International Inc.Inventors: Axel duMoulin, Jutta Muller-Derlich
-
Patent number: 5824839Abstract: Disclosed are methods that achieve i) site-directed delivery, ii) in situ amplification, and iii) sustained expression of an exogenous gene product within renal glomeruli. An exogenous gene, E. coli .beta.-galactosidase, was introduced into cultured rat mesangial cells using a replication-defective retrovirus, and stable infectants were administered to a rat kidney via the renal artery. In the injected kidney, the engineered, cultured mesangial cells populated 40% of glomeruli site-specifically. The gene product was detected throughout a 14-week period of observation. In an alternative method, engineered, cultured mesangial cells were injected into a kidney subjected to an antibody that induces mesangiolysis followed by mesangial regeneration. Under these conditions, expression of .beta.-galactosidase was dramatically amplified in situ and high level expression continued for at least 8 weeks.Type: GrantFiled: April 9, 1997Date of Patent: October 20, 1998Assignee: The Jikei University School of MedicineInventor: Masanori Kitamura